Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Prevalence of Kidney transplantation in highly sensitized patients
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of Kidney transplantation in highly sensitized patients

1 evidence topic · 1 source

Transplant-waiting-list population

“Across the U.S. and Europe, highly sensitized patients comprise around 10-15% of the total of patients on transplant waiting lists.” (opens the source at this quote in a new tab)